

# Christoph Schramm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4437458/publications.pdf>

Version: 2024-02-01

115  
papers

7,583  
citations

76196

40  
h-index

56606

83  
g-index

118  
all docs

118  
docs citations

118  
times ranked

8529  
citing authors

#	ARTICLE	IF	CITATIONS
1	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	3.6	1,553
2	The Translational Landscape of the Human Heart. <i>Cell</i> , 2019, 178, 242-260.e29.	13.5	407
3	Genome-Wide Association Analysis in Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2010, 138, 1102-1111.	0.6	325
4	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. <i>Gastroenterology</i> , 2014, 147, 443-452.e5.	0.6	268
5	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	6.3	257
6	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
7	Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. <i>Nature Genetics</i> , 2011, 43, 17-19.	9.4	221
8	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	3.6	204
9	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
10	Pregnancy in Autoimmune Hepatitis: Outcome and Risk Factors. <i>American Journal of Gastroenterology</i> , 2006, 101, 556-560.	0.2	200
11	TGF-Î²-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. <i>Journal of Hepatology</i> , 2014, 61, 594-599.	1.8	185
12	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , 2017, 49, 588-608.	1.0	154
13	Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. <i>Journal of Hepatology</i> , 2015, 62, 1349-1356.	1.8	145
14	Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2013, 58, 1084-1093.	3.6	132
15	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , 2014, 60, 1290-1303.	1.8	129
16	Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. <i>Journal of Hepatology</i> , 2016, 65, 769-775.	1.8	127
17	Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. <i>Liver Transplantation</i> , 2016, 22, 42-52.	1.3	111
18	Recommendations on the use of magnetic resonance imaging in PSCâ€“A position statement from the International PSC Study Group. <i>Hepatology</i> , 2017, 66, 1675-1688.	3.6	104

#	ARTICLE	IF	CITATIONS
19	Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 754-763.	1.8	90
20	Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 445-453.	2.4	84
21	Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues. <i>Gastroenterology</i> , 2017, 153, 1404-1415.	0.6	80
22	Alterations of the bile microbiome in primary sclerosing cholangitis. <i>Gut</i> , 2020, 69, 665-672.	6.1	80
23	Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. <i>Gut</i> , 2017, 66, 753-754.	6.1	70
24	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2021, 160, 1784-1798.e0.	0.6	69
25	Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1733-1738.	2.4	66
26	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2022, 76, 841-849.	1.8	64
27	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	2.4	57
28	24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. <i>Journal of Hepatology</i> , 2015, 62, 871-878.	1.8	55
29	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2068-2075.e2.	2.4	55
30	Depression and anxiety in patients with different rare chronic diseases: A cross-sectional study. <i>PLoS ONE</i> , 2019, 14, e0211343.	1.1	55
31	A disease-specific decline of the relative abundance of <i>Bifidobacterium</i> in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1417-1428.	1.9	55
32	Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and Anemia. <i>Gastroenterology</i> , 2016, 151, 999-1010.e3.	0.6	53
33	Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 329-336.	0.6	53
34	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 634-646.	1.8	51
35	Testosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis. <i>Journal of Immunology</i> , 2015, 194, 2522-2530.	0.4	50
36	Monocytes as Potential Mediators of Pathogen-Induced T <sub>H</sub> 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). <i>Hepatology</i> , 2020, 72, 1310-1326.	3.6	50

#	ARTICLE	IF	CITATIONS
37	Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 414-423.	1.8	49
38	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	1.8	47
39	Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. <i>PLoS ONE</i> , 2018, 13, e0201170.	1.1	46
40	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2016, 11, e0164224.	1.1	45
41	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
42	Clinical management of autoimmune hepatitis. <i>United European Gastroenterology Journal</i> , 2019, 7, 1156-1163.	1.6	42
43	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
44	Bile Acids, the Microbiome, Immunity, and Liver Tumors. <i>New England Journal of Medicine</i> , 2018, 379, 888-890.	13.9	41
45	Acute Ebola virus disease patient treatment and health-related quality of life in health care professionals: A controlled study. <i>Journal of Psychosomatic Research</i> , 2016, 83, 69-74.	1.2	39
46	Primary liver transplantation for autoimmune hepatitis: A comparative analysis of the European Liver Transplant Registry. <i>Liver Transplantation</i> , 2010, 16, NA-NA.	1.3	38
47	Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture. <i>Gastroenterology</i> , 2018, 155, 1366-1371.e3.	0.6	36
48	The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases?. <i>Frontiers in Immunology</i> , 2020, 11, 1567.	2.2	34
49	Persistent SOMatic symptoms ACROSS diseases – from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). <i>BMJ Open</i> , 2022, 12, e057596.	0.8	33
50	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	1.8	33
51	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. <i>Journal of Hepatology</i> , 2021, 74, 312-320.	1.8	31
52	Interferon-Î³-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice. <i>Journal of Hepatology</i> , 2019, 71, 773-782.	1.8	30
53	Autoimmune hepatitis – update on clinical management in 2017. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 617-625.	0.7	28
54	Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. <i>Gut</i> , 2016, 65, 1230-1232.	6.1	27

#	ARTICLE	IF	CITATIONS
55	Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells. PLoS ONE, 2017, 12, e0182532.	1.1	27
56	Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, 941-953.	1.8	27
57	Sex-related factors in autoimmune liver diseases. Seminars in Immunopathology, 2019, 41, 165-175.	2.8	27
58	Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. European Radiology, 2022, 32, 923-937.	2.3	27
59	SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European Gastroenterology Journal, 2022, 10, 319-329.	1.6	27
60	Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling. Journal of Hepatology, 2017, 66, 798-805.	1.8	26
61	Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. Journal of Hepatology, 2019, 71, 783-792.	1.8	26
62	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. Clinical Gastroenterology and Hepatology, 2020, 18, 1609-1617.e4.	2.4	25
63	Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Liver Transplantation, 2020, 26, 866-877.	1.3	25
64	Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of <i>Trichocladium griseum</i> and <i>Candida</i> species. Gut, 2020, 69, 1890-1892.	6.1	25
65	Circulating microbiome in patients with portal hypertension. Gut Microbes, 2022, 14, 2029674.	4.3	22
66	The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts. Seminars in Immunopathology, 2022, 44, 485-507.	2.8	22
67	Transient Elastography in Primary Sclerosing Cholangitis—the Value as a Prognostic Factor and Limitations. Gastroenterology, 2014, 147, 542-543.	0.6	21
68	Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice. Hepatology, 2016, 64, 508-521.	3.6	21
69	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
70	Disease Duration and Stage Influence Bone Microstructure in Patients With Primary Biliary Cholangitis. Journal of Bone and Mineral Research, 2018, 33, 1011-1019.	3.1	20
71	Human liver-derived CXCR6+NK cells are predominantly educated through NKG2A and show reduced cytokine production. Journal of Leukocyte Biology, 2019, 105, 1331-1340.	1.5	20
72	Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterology Journal, 2020, 8, 667-674.	1.6	20

#	ARTICLE	IF	CITATIONS
73	Autoimmune hepatitis on the rise. <i>Journal of Hepatology</i> , 2014, 60, 478-479.	1.8	19
74	Immunology of hepatic diseases during pregnancy. <i>Seminars in Immunopathology</i> , 2016, 38, 669-685.	2.8	19
75	CCL21 expression and accumulation of CCR7 <sup>+</sup> NK cells in livers of patients with primary sclerosing cholangitis. <i>European Journal of Immunology</i> , 2019, 49, 758-769.	1.6	18
76	IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. <i>Journal of Hepatology</i> , 2021, 74, 919-930.	1.8	18
77	The genetic architecture of primary biliary cholangitis. <i>European Journal of Medical Genetics</i> , 2021, 64, 104292.	0.7	18
78	Magnetic Resonance Imaging in Primary Sclerosing Cholangitis – Current State and Future Directions. <i>Seminars in Liver Disease</i> , 2019, 39, 369-380.	1.8	17
79	Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 431-438.	0.2	17
80	Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. <i>Frontiers in Immunology</i> , 2019, 10, 1065.	2.2	16
81	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020, 40, 2164-2171.	1.9	16
82	No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1806-1812.	2.4	15
83	A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 226-233.e3.	2.4	15
84	Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice. <i>Journal of Hepatology</i> , 2021, 74, 407-418.	1.8	15
85	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	1.9	15
86	Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100321.	2.6	14
87	Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2022, 22, 626-633.	2.6	14
88	Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease. <i>Communications Biology</i> , 2022, 5, 80.	2.0	12
89	Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. <i>PLoS ONE</i> , 2018, 13, e0190005.	1.1	11
90	CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans. <i>Frontiers in Immunology</i> , 2019, 10, 1247.	2.2	11

#	ARTICLE	IF	CITATIONS
91	Aryl Hydrocarbon Receptor Activity in Hepatocytes Sensitizes to Hyperacute Acetaminophen-Induced Hepatotoxicity in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 371-388.	2.3	11
92	Oxysterol 7- $\beta$ -Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality. <i>Cells</i> , 2021, 10, 2656.	1.8	10
93	Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care. <i>Journal of Hepatology</i> , 2022, 77, 250-251.	1.8	9
94	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2015, 10, e0140525.	1.1	8
95	Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis. <i>Pediatrics</i> , 2016, 138, .	1.0	8
96	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1391-1396.	0.6	8
97	Efficacy of a Brief, Peer-Delivered Self-management Intervention for Patients With Rare Chronic Diseases. <i>JAMA Psychiatry</i> , 2021, 78, 607.	6.0	8
98	Role of ultrasound measuring position and ventilation pressure in determining correct tube size in children. <i>Paediatric Anaesthesia</i> , 2017, 27, 1241-1246.	0.6	6
99	Concise Commentary: Why Cholangioscopy for Indeterminate Biliary Strictures in PSC Is Still Not Good Enough. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1479-1480.	1.1	6
100	Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1532-1544.	1.8	5
101	Natural killer T cells: Novel players in biliary disease?. <i>Hepatology</i> , 2015, 62, 999-1000.	3.6	4
102	How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?. <i>Visceral Medicine</i> , 2015, 31, 173-177.	0.5	3
103	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. <i>Journal of Hepatology</i> , 2020, 73, 1285-1287.	1.8	3
104	Bone microarchitecture in patients with autoimmune hepatitis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1316-1325.	3.1	3
105	Reply to: "Anti-TNF-induced autoimmune hepatitis". <i>Journal of Hepatology</i> , 2014, 61, 170-171.	1.8	2
106	LUCASÂ® leaving its footprints during cardiopulmonary resuscitation. <i>Visual Journal of Emergency Medicine</i> , 2019, 17, 100666.	0.0	2
107	PSC: Novel disease associations providing pathogenetic clues?. <i>Journal of Hepatology</i> , 2014, 60, 687-688.	1.8	1
108	Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature. <i>GastroHep</i> , 2019, 1, 33-44.	0.3	1

#	ARTICLE	IF	CITATIONS
109	Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101760.	0.7	1
110	Reply:. Hepatology, 2009, 49, 1783-1783.	3.6	0
111	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1063-1064.	2.4	0
112	Editorial: gut microbiota profile in patients with autoimmune hepatitis—a clue for adjunctive probiotic therapy? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 394-395.	1.9	0
113	Aneurysm of the ascending aorta and dilation of the pulmonary trunk in a patient with homocysteinemia. Vasa - European Journal of Vascular Medicine, 2020, 49, 151-152.	0.6	0
114	Colonisation of bile ducts with Enterococcus sp. associates with the prognosis of Primary Sclerosing Cholangitis. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0
115	Low antibody titers after second SARS-CoV-2 vaccination in patients with autoimmune hepatitis. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0